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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARY
Studies of developmental pathways of hematopoiet-
ic stem cells (HSCs) have defined lineage relation-
ships throughout the blood system. This is relevant
to acute myeloid leukemia (AML), where aggressive-
ness and therapeutic responsiveness can be influ-
enced by the initial stage of transformation. To
address this, we generated a mouse model in which
the mixed-lineage leukemia/eleven-nineteen-leuke-
mia (MLL-ENL) transcription factor can be con-
ditionally activated in any cell type. We show that
AML can originate from multiple hematopoietic
progenitor subsets with granulocytic and monocytic
potential, and that the normal developmental posi-
tion of leukemia-initiating cells influences leukemic
development. However, disease failed to arise
from HSCs. Although it maintained or upregulated
the expression of target genes associated with
leukemic development, MLL-ENL dysregulated the
proliferative and repopulating capacity of HSCs.
Therefore, the permissiveness for development of
AML may be associated with a narrower window
of differentiation than was previously appreciated,
and hijacking the self-renewal capacity of HSCs
by a potent oncogene is insufficient for leukemic
development.INTRODUCTION
The hematopoietic system is normally under the control of
environmentally derived signals and an intricate network of
finely tuned transcriptional programs (Orkin and Zon, 2008)
that enable rare hematopoietic stem cells (HSCs) to give rise to
differentiated progeny in a hierarchical fashion. Therefore,
knowledge about the functional and molecular properties of
defined hematopoietic progenitor cells (HPCs) at different1246 Cell Reports 9, 1246–1255, November 20, 2014 ª2014 The Autstages of maturation could provide insights into the etiology of
acute myeloid leukemia (AML).
Balanced chromosomal translocations that result in fusion
proteins with aberrant transcriptional activities are frequent
initiating events in AML. A prototype family of such factors is
represented by mixed lineage leukemia-1 (MLL1) gene fusions.
In previous studies, retroviral introduction of MLL-ENL or MLL-
AF9 fusion genes into committed granulocyte-macrophage pro-
genitors (GMPs) resulted in AML (Cozzio et al., 2003; Krivtsov
et al., 2006), demonstrating that MLL-fusion-mediated trans-
formation can involve an early activation of self-renewal. This
property is not normally associated with GMPs. However, not
all types of HPCs can act as leukemia-initiating cells (LICs).
Introduction of MLL-ENL in proliferation-competent B cells did
not result in disease (Cano et al., 2008), and AML failed to
develop from megakaryocyte/erythroid progenitors and com-
mon lymphoid progenitors (CLPs) (Cozzio et al., 2003). In con-
trast to these data, it was shown that CLPs readily gave rise to
AML, but GMPs failed to produce disease, in an endogenous
knockin model of MLL-AF9 (Chen et al., 2008).
While it appears clear that cells can lose competence for
leukemic transformation with differentiation, the question re-
mains as to whether the most primitive HSCs are imbued with
leukemogenic competence. Given the inherent self-renewal
and cytoprotective properties of HSCs, and assuming that
such properties are retained at the apex of the leukemia hierar-
chy, leukemia initiation at the level of HSCs might be associated
with a particularly poor prognosis. Although previous studies
have suggested that HSCs are potent LICs (Chen et al., 2008;
Cozzio et al., 2003; Krivtsov et al., 2013), and even proposed
that HSCs are the predominant targets for AML (Chen et al.,
2008; Krivtsov et al., 2013), it was shown that HSCs were not
susceptible to transformation in Mn1-induced AML unless
Meis1 and Hoxa9/Hoxa10 were also cointroduced (Heuser
et al., 2011). However, this issue is difficult to address, and in
the specific case of Mn1-induced leukemia, is complicated
by the fact that the forced expression of Hoxa9/10 and Meis1
in many contexts is leukemic by itself. Other concerns might
also apply. For instance, the use of gamma-retroviral models
requires induction of proliferation, which, given the quiescenthors
Figure 1. MLL-ENL-Driven Leukemia from Myeloid Progenitors Is Influenced by Stage of Maturation
(A) Schematic depiction of the hematopoietic progenitor hierarchy.
(B) Absolute quantification of MLL-ENL and endogenous Mll1 mRNA expression in Col1a1-tetO-MLL/ENL HSPCs induced for 14 days in vivo and retrovirally
delivered MLL-ENL (MIG MLL-ENL). Depicted are copies of MLL-ENL (blue bars) and endogenous Mll1 (red bars) per cell ± SD from three independent
experiments.
(C) Experimental strategy used in subsequent in vivo experiments.
(D) A total of 5,000 pGMs or GMPs were isolated from Col1a1-tetO-MLL/ENL mice and transplanted competitively into lethally irradiated recipients. PB was
analyzed at the indicated time points for myeloid contribution (n = 13 recipients of pGMs and 11 recipients of GMPs from two separate experiments; individual
mice are depicted).
(E) Event-free survival of mice that received MLL-ENL-induced GMPs (n = 11 recipients, red line), pGMs (n = 13 recipients, solid blue line), or uninduced pGMs
(n = 10 recipients, black line), and secondary recipients of pGM-derived primary leukemias (n = 8 recipients, dashed blue line). Statistics were determined by
Student’s two-tailed t test or log rank test (Mantel-Cox test for survival). *p < 0.05; ***p < 0.001; ****p < 0.0001; n.s., not significant.
See also Figure S2.nature of HSCs, is a potentially significant alteration (Pietras
et al., 2011). The purity of isolated HSC subsets can be another
confounding factor, as most previous studies utilized only
partially purified HSCs intermingled with other, less self-renew-
ing multipotent progenitors (MPPs). Cancer stem cells in human
AMLs appear to share common features with such progenitors
(Goardon et al., 2011), although information about LICs is difficult
to deduce from established leukemia, in which a spectrum of
secondary mutations and epigenetic changes has evolved. The
issue is further complicated by the fact that the fusion oncogenes
themselves can alter the normal rules of differentiation (Drynan
et al., 2005).
Here, we developed a transgenic mouse model that allows for
the conditional activation of a human MLL-ENL fusion oncogene
in otherwise normal cells. Combined with prospective isolations
of candidate LICs and adoptive transfers, this approach allowed
us to examine leukemia initiation and competence throughout
the early hematopoietic hierarchy in detail.Cell ReRESULTS
Establishment and Functional Validation of a
Doxycycline-Inducible MLL-ENL Mouse Model
To create an inducible model for the human MLL-ENL fusion
gene, we used the KH2 embryonic stem cell (ESC) system
(Beard et al., 2006), in which the M2 reverse tetracycline
transactivator (M2-rtTA) is driven constitutively under the
Rosa26 promoter. MLL-ENL was targeted to the 30 UTR of
the Col1a1 gene under tetracycline-regulated control, allowing
for MLL-ENL expression upon doxycycline (Dox) supplemen-
tation (Figure S1A). Following in vivo induction, we assessed
MLL-ENL expression in different hematopoietic stem and
progenitor cells (HSPCs; Figure 1A). Although clear expression
of MLL-ENL was detected in all of the HSPC subsets evalu-
ated, the levels were in stark contrast to the very high levels
observed using retroviral approaches (Chen et al., 2008;
Figure 1B).ports 9, 1246–1255, November 20, 2014 ª2014 The Authors 1247
Leukemic Competence, Disease Latency, and Patterns
of Preleukemic Growth Are Hierarchically Structured
among Myeloid Progenitors
Using retroviral delivery, Cozzio et al. (2003) showed that both
common myeloid progenitors (CMPs) and GMPs could initiate
AML. Whereas GMPs represent a rather pure population of
lineage-restricted cells (Akashi et al., 2000), the CMP population
is more heterogeneous and includes precursors for GMPs
(pGMs), bipotential megakaryocyte/erythroid cells (preMeg/Es),
monolineage committed megakaryocyte progenitors (MkPs),
and some early erythroid (preCFU-E) progenitors (Figure 1A;
Pronk et al., 2007). We hypothesized that pGMs could represent
candidate LICs, and therefore we first asked whether the related
pGM and GMP subsets could exhibit differential responses to
MLL-ENL.
We adopted an approach whereby limited numbers of defined
HSPCs from Col1a1-tetO-MLL/ENL mice were isolated and
transplanted into wild-type (WT) recipient mice under Dox
administration (Figure 1C). Starting at 4 weeks after transplan-
tation, the contribution of test cells was evaluated biweekly.
We observed a very limited donor myeloid contribution from
MLL-ENL-induced GMPs (Figure 1D, upper panel). All mice
that received GMPs survived without noticeable abnormalities
until week 16. However, one recipient at week 18, two at week
21, and one at week 26 were found to be sick. The remaining
seven mice in this group remained disease free (Figure 1E).
Although pGMs and GMPs are believed to be closely related
(Pronk et al., 2007), their in vivo behaviors in response to MLL-
ENL were strikingly different. MLL-ENL induction led to a sub-
stantial pGM-derived myeloid contribution in all mice at 4 weeks
(Figure 1D, lower panel). This was associated with subsequent,
mostly sharp drops in myeloid contribution up to week 8. There-
after, we observed rapid rebounds in the levels of peripheral
blood (PB) myeloid cells in most (11/13) of the pGM-transplanted
mice (Figure 1D, lower panel). Further analysis confirmed a
clinical progression to myeloid malignant transformation (Fig-
ure S2B; data not shown). Transplantation of bone marrow
(BM) cells from diseasedmice into secondary hosts led to a rapid
propagation of disease (Figure 1E).
MLL-ENL Is a Potent Inducer of Leukemia in Multiple
Progenitor Types but Fails to Induce Leukemia
from the Most Primitive Subsets
We next asked whether and how MLL-ENL might affect other
primitive progenitors. We began by assessing CLPs. In agree-
ment with a limited myeloid potential of these cells, five out of
seven untreated mice failed to show any evidence of test-cell-
derivedmyeloid reconstitution, and the remainingmice displayed
a very low myeloid contribution (0.5% and 0.1%, respectively;
Figure 2A). In contrast, MLL-ENL induction of CLPs led to a
myeloid contribution in all mice (mean 1.5%, range 0.5%–2.8%
at 4 weeks) that persisted at all time points investigated (Fig-
ure 2A). At 10 and 16 weeks posttransplantation, two mice that
received MLL-ENL-induced CLPs died. Subsequently, the re-
maining mice exhibited sudden elevations of PB myeloid cells
and presented with AML (Figures 2A and 2D). Secondary trans-
plantations of BM cells from diseased CLP-transplanted mice
resulted in diseasedevelopmentwith a short latency (FigureS3A).1248 Cell Reports 9, 1246–1255, November 20, 2014 ª2014 The AutWe next tested whether MLL-ENL could also affect preMeg/
Es, an early megakaryocytic/erythroid restricted progenitor
subset. However, we could not detect any donor-derived recon-
stitution to the myeloid, B cell, or T cell lineages from such cells,
and the mice remained healthy until the experiment’s endpoint
(Figure 2D).
In previous studies, it was suggested that HSCs, but not
the more downstream GMPs, could initiate AML (Chen et al.,
2008). However, in those studies, candidate HSCs were isolated
as LinSca1+ckit+ (LSK) cells, which in addition to a minor
portion of HSCs contain a larger fraction of various MPP cells
(Oguro et al., 2013). Therefore, we investigated this issue more
closely in our model by first evaluating LSKCD48+CD150 cells
(referred to as granulocyte-monocyte-lymphoid progenitors
[GMLPs]). GMLPs represent the major LSK subset and are
functionally distinct from HSCs (Kiel et al., 2005; Oguro et al.,
2013; Pronk et al., 2007). Confirming this, the contribution of
uninduced GMLPs to the myeloid lineage, a reliable indicator
of ongoing HSC activity, was completely absent short term after
transplantation (Figure 2A). By contrast, MLL-ENL profoundly
affected the in vivo reconstitution activity of GMLPs. Myeloid
chimerism from Dox-induced GMLPs was very high at 4 weeks
after transplantation (Figure 2A), although this declined some-
what at subsequent time points. At 12 weeks after transplanta-
tion, we began to observe an upsurge in myeloid chimerism
in these mice. Two induced GMLP recipients spontaneously
died following the 14-week analysis, and the remaining mice
developed AML within 16 weeks (Figure 2D). Serial transplanta-
tion resulted in a rapid disease onset (Figure S3A). With GMLPs,
a pronounced effect of MLL-ENL induction extended also to
the lymphoid lineages, with high contributions to the peripheral
B and T cell lineages (data not shown). However, the rapid rise
in chimerism was restricted to myeloid cells.
Next, we evaluated LSKCD48CD150 cells (hereafter
referred to as MPPs). This MPP population has not been exten-
sively characterized. Therefore, we first probed the normal in vivo
capacity of these cells (Figure S3B). We then competitively
transplanted 500 MPPs per recipient without or with MLL-ENL
induction. The contribution to the myeloid lineages was slightly
higher in MLL-ENL-exposed MPPs at 4 weeks, but dropped at
later time points (Figure 2A). From induced MPPs, one mouse
died after the blood analysis conducted 20weeks posttransplan-
tation. However, somewhat surprisingly, the remaining mice did
not show any changes in donor-derived myeloid chimerism or
signs of disease development over a period of 50 weeks
(Figure 2D).
Finally, we investigated how MLL-ENL induction would affect
highly purifiedHSCs.We isolated LSKCD150+CD48HSCs from
Col1a1-tetO-MLL/ENL mice and competitively transplanted 100
or 1,000 of these cells per mouse with or without MLL-ENL
induction. At the lower dose, all uninduced mice were highly
reconstituted (Figure 2B, upper left). In contrast, administration
of Dox severely compromised the reconstitution potential of
Col1a1-tetO-MLL/ENL HSCs (Figure 2B, upper right). Similarly,
at the higher cell dose, all control mice were robustly reconsti-
tuted (Figure 2B, lower left), whereas two of 13 Dox-treated
hosts failed to display HSC-derived reconstitution. The overall
myeloid reconstitution in the remaining MLL-ENL-induced micehors
Figure 2. MLL-ENL-Driven Leukemia Develops from Progenitors Rather than Stem Cells
(A) Mice were competitively transplanted with 500 CLPs (top), 5,000 GMLPs (middle), or 500 MPPs (bottom) and then the donor contribution to the myeloid
lineages in uninduced (closed circles) and induced (open circles) mice was evaluated. Data are from six or sevenmice per group. ForMPPs, graphs show average
chimerism ± SD, whereas individual mice are indicated for GMLPs and CLPs.
(B) PB analyses showing the donor-derived contribution fromHSCs to themyeloid lineages after transplantation of 100 (upper panel; n = 7 in each group) or 1,000
(lower panel; n = 11 for uninduced and n = 13 for induced) HSCs. Individual recipients are depicted. The number of mice without detectable reconstitution is
indicated along the x axis. Two representative experiments of four are shown.
(C) Secondary transplantation of unfractionated BM cells fromMLL-ENL-induced HSCs. BM cells from three primary HSC-transplanted mice (MLL-ENL induced
for 24 weeks) were transplanted into three sublethally irradiated WT recipients (three recipients per primary donor) under continuous MLL-ENL induction. The
mean (± SD) frequency of donor myeloid cells for each primary donor is shown.
(D) Event-free survival of mice transplanted with HSCs (red), MPPs (blue), GMLPs (green), CLPs (brown), or pMeg/Es (black).
See also Figure S3.was substantially lower compared with controls and gradually
declined (Figure 2B, lower right). Strikingly, we never observed
any incidence of myeloproliferation/leukemia from MLL-ENL-
inducedHSCs. Since AML can develop relatively late (Figure 1E),
we extended the monitoring period for HSC-transplanted mice
by serial transplantation. Secondary hosts were monitored for
an additional 24 weeks (Figure 2C) without showing any signs
of disease. The progressive reduction in HSC reconstitution
over time led us to speculate that MLL-ENL leads to a block in
differentiation. For instance, one could hypothesize that HSCs
are unable to differentiate and instead self-renew excessively
in response to MLL-ENL. To investigate this, we sacrificed a
cohort of mice transplanted with 1,000 HSCs and investigated
the contributions of MLL-ENL-induced HSCs to the various
HSPC fractions. However, we did not observe a block at any
distinct progenitor stage, but rather found an overall reduction
in all HSPC subsets assessed (Figure S3C).Cell ReIntrinsic Protection against Transformation
at the HSC Level
The failure of the HSCs and MPPs to transform was a surprising
result. Therefore, we decided to further characterize the differen-
tial responses by initiating cultures with HSCs, MPPs, GMLPs,
and pGMs in the absence or presence of Dox. We also delayed
addition of Dox to the cultures. At 10 days after MLL-ENL onset,
we evaluated proliferation relative to uninduced cultures. In
accordancewith their in vivo behavior, GMLPs and pGMs gained
an enhanced proliferative capacity immediately following sup-
plementation with Dox (Figure 3A). Of note, Dox addition at
days 3 and 4 to pGMs failed to provide an additional proliferative
advantage. In striking contrast, continuous MLL-ENL induction
in HSCs led to a dramatic reduction in cellular output (Figure 3A).
This was not due to a selective toxicity (Figure S4A; data not
shown). Proliferation in HSC cultures to which Dox was added
at days 1 and 2 was also lower than that observed in noninducedports 9, 1246–1255, November 20, 2014 ª2014 The Authors 1249
Figure 3. MLL-ENL Expression Induces Leukemic Activity following HSC Differentiation but Restricts HSC Activity in a Dose-Dependent
Manner
(A) Effect of delayed MLL-ENL induction on the proliferation of primitive hematopoietic progenitors. Dox was added at the indicated time points after initiation of
cultures with HSCs (red), MPPs (brown), GMLPs (green), and pGMs (blue). Cell numbers were enumerated 10 days after addition of Dox, and proliferation rates
are shown relative to uninduced cultures.
(B) Kaplan-Myer curve depicting the survival of mice transplanted with HSCs fromCol1a1-tetO-MLL/ENLmice under continuous or delayedMLL-ENL induction.
(C) Myeloid contribution at weeks 4 and 14 in the presence and absence of Dox following transplantation of 100Col1a1-tetO-MLL/ENLHSCs that were previously
induced for 14 days (n = 7 mice/group).
(D) Quantification of MLL-ENL and endogenousMll1 expression in pGMs isolated fromHSC-transplantedmice, GMPs from pGM-transplantedmice, and HSPCs
isolated from Col1a1-tetO-MLL/ENL mice induced for 14 days in vivo (the latter expression values also shown in Figure 2B). Shown are the transcript counts per
cell of MLL-ENL and endogenous Mll1 ± SD from three biological replicates.
(E) Quantification of MLL-ENL expression in HSCs and pGMs from 3-day induced Col1a1-tetO-MLL/ENL mice. Depicted are copy numbers ± SD.
(F) Mice were competitively transplanted with 650 HSCs and then the donor contribution to the myeloid lineage in the PB of uninduced (closed circles) and mice
induced with standard (squares) and high-Dox (triangles) food pellets (n = 7 mice/group) was evaluated. Statistics were determined by Student’s two-tailed t test
or log rank test (Mantel-Cox test for survival). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; n.s., not significant. Data shown are from one experiment of two
with similar results.
See also Figure S4.cultures. However, when Dox was added later, we observed
increases in proliferative output (Figure 3A). MPPs responded
similarly to HSCs, although they gained a proliferative advantage
more rapidly following delayed induction. These findings led
us to investigate whether the progeny of transplanted HSCs
are leukemia competent. We transplanted 1,000 HSCs with or
without MLL-ENL induction. After 4 weeks, noninduced mice
were administered Dox. Although no HSC recipients under
continuous MLL-ENL expression developed disease, all mice
that were administered Dox 4 weeks following transplantation
developed AML (Figure 3B).
A potential explanation for the reduced in vivo contribution
from MLL-ENL-induced HSCs could be a compromised in vivo1250 Cell Reports 9, 1246–1255, November 20, 2014 ª2014 The Authoming ability. To investigate this, we isolated HSCs from
Col1a1-tetO-MLL/ENL mice provided with Dox food pellets for
14 days, and transplanted 100 HSCs from these mice into
mice with or without MLL-ENL induction. Although no significant
differences in donor chimerism were observed at 4 weeks,
progressive reductions in donor chimerism upon MLL-ENL
induction were observed over the period of 14 weeks (Figure 3C;
data not shown). Again, no leukemia developed in any mice.
An alternative approach generated similar results (Figure S4B),
suggesting that compromised homing is unlikely to underlie
the functional shortcomings of MLL-ENL-induced HSCs.
Although our data had demonstrated a progressive decline
in HSC activity upon MLL-ENL induction, we were perplexedhors
that leukemia did not develop, given that prominent HSC-
derived reconstitution was observed in most recipients. This
included the generation of otherwise leukemia-competent
progenitors (Figure S3C). To address this issue, we determined
the expression levels of MLL-ENL in pGMs developing from
HSCs under MLL-ENL induction. These analyses revealed that
in comparison with pGMs isolated from Dox-induced Col1a1-
tetO-MLL/ENL mice, MLL-ENL expression was significantly
lower (3.8-fold) in pGMs from transplanted and induced HSCs.
Reduced expression was not observed in GMPs isolated from
pGM-transplanted mice (Figure 3D), a scenario in which AML
develops. This led us to hypothesize that there might be a selec-
tion against HSCs with higher MLL-ENL levels. To address this,
we also assessed HSC activity with higher MLL-ENL expression.
This revealed that higher MLL-ENL dosages (Figure 3E) severely
compromised HSC-derived reconstitution (seven out of seven
mice without donor chimerism; Figure 3F).
Transcriptional Signatures upon Leukemia Initiation
In a previous study, Armstrong et al. (2002) found that MLL-
fusion leukemias constitute a distinct entity of AML that is
distinguishable by its gene-expression patterns. However,
gene-expression studies of established leukemias have pro-
vided little information about the initial transcriptional changes
that occur in preleukemic cells. Therefore, we decided to inves-
tigate the immediate transcriptional responses to MLL-ENL.
We isolated WT and Col1a1-tetO-MLL/ENL pGMs and HSCs
that were briefly exposed to Dox (48 hr) in vitro and subjected
them to RNA sequencing (RNA-seq). The induction of MLL-
ENL resulted in evident transcriptional alterations in both cell
types (Figure 4A; Table S1).
Together, our functional data supported a scenario in which
inhibition of differentiation is a feature of MLL-ENL-driven
leukemic development. To investigate this in detail from a mo-
lecular perspective, we used Gene Set Enrichment Analysis
(GSEA) (Figure 4B). This revealed that upregulated genes in
induced HSCs were strongly associated with the normal HSC
state, whereas downregulated genes correlated with the
more-differentiated GMLPs (p < 0.001; Figure 4B). Similarly,
the upregulated genes in MLL-ENL-induced pGMs were firmly
associated with normal pGMs, and the downregulated genes
correlated with GMPs (p < 0.001; Figure 4B). Thus, inhibition
of differentiation appears to be a key early event in preleukemic
cells that applies to both leukemia-competent pGMs and
leukemia-incompetent HSCs. To identify additional molecular
properties, we searched for overrepresented Gene Ontology
(GO) categories among the differentially expressed genes.
The GO category ‘‘Cell cycle arrest’’ showed significant enrich-
ment following MLL-ENL induction specifically in HSCs (Fig-
ure 4C, left), which was confirmed by direct cell-cycle assess-
ments (Figure 4C, right).
If MLL-ENL is capable of restricting both the differentiation
and proliferation of HSCs, it is reasonable to assume that
transient MLL-ENL expression could be beneficial in terms of
preserving HSC activity. To test this, we maintained HSCs
from Col1a1-tetO-MLL/ENL mice in the presence or absence
of Dox for 10 days and then evaluated their activity. HSCs
cultured without MLL-ENL induction proliferated vigorously butCell Refailed to provide long-term multilineage reconstitution (Fig-
ure 4D). By contrast, cultured and MLL-ENL-induced HSCs
displayed robust long-term reconstitution (Figure 4D). Thus,
transient MLL-ENL expression preserves at least some degree
of functional HSC activity.
The differential effect of MLL-ENL on proliferation led us to
speculate that the effect of MLL-ENL was guided strictly by the
proliferative status of the target cells. It is well established that
fetal liver HSCs are more actively cycling than adult HSCs.
Therefore, in a final set of in vivo experiments, we transplanted
embryonic day 14.5 (E14.5) fetal liver HSCs from Col1a1-tetO-
MLL/ENL mice with or without MLL-ENL induction. However,
similar to what was observed for adult HSCs,MLL-ENL induction
severely compromised the reconstitution potential of fetal liver
HSCs in a dose-dependent manner (Figure 4E).
DISCUSSION
Leukemic transformation of primary hematopoietic cells is often
regarded as a plastic process wherein various hematopoietic
subpopulations can serve as target cells of the disease. At the
same time, leukemias present with diverse lineage-associated
phenotypes (e.g., myeloid, lymphoid, and, less frequently,
erythroid/megakaryocytic forms). This lineage representation is
indicative of an interplay between the normal differentiation
potential of the target cell and the instructive/permissive nature
of the oncogene. However, a more exact identity of the cell(s)
of origin across the spectrum of various subtypes of leukemia
remains to be determined.
Using our model, we show that the leukemic potential lies
within a relatively narrowwindow of the hematopoietic hierarchy.
Transplantation and induction of prospectively isolated pGMs
and GMPs, two closely related cellular states (Pronk et al.,
2007), resulted in dramatically different disease development.
This observation is in agreement with previous studies on a
separate MLL fusion gene (MLL-AF9) and the Meningioma 1
(Mn1) model of leukemia (Chen et al., 2008; Heuser et al.,
2011). However, in this work, we were able to pinpoint the devel-
opmental switch that limits the leukemic potential. We did this
by assaying pGMs rather than the CMP fraction, which repre-
sents a more heterogeneous population of hematopoietic pro-
genitors (Pronk et al., 2007). It is of note that Mn1 expression is
lost at the GMP stage (Heuser et al., 2011), but the combinatorial
overexpression ofMn1, Meis1, andHoxa9/Hoxa10 can reinforce
a susceptibility to transformation of these cells. Presumably,
this is also relevant for MLL-fusion-mediated transformation,
as both Meis1 and Hox genes are prominent target genes for
these fusions, including in our model (data not shown).
Contrary to previous work (Cozzio et al., 2003), we demon-
strate that CLPs are highly susceptible to MLL-ENL-mediated
transformation. We show that CLPs initially respond to MLL-
ENL induction with a continued contribution to the lymphoid
lineages and a low, albeit detectable, myeloid output. However,
all recipients of induced CLPs succumbed to myeloid leukemia
with a germline B cell receptor configuration (data not shown).
We believe the discrepancy between our study and previous
work on this issue may be due to the different experimental
approaches used. An obvious advantage with inducibleports 9, 1246–1255, November 20, 2014 ª2014 The Authors 1251
Figure 4. MLL-ENL Induces Both Shared and Cell-Context-Dependent Transcriptional Responses
(A) Venn diagrams showing the number and overlap of up- and downregulated genes in HSCs and pGMs upon brief exposure to MLL-ENL (based on triplicate
RNA-seq samples per group).
(B) The 500 most up- and downregulated genes in both cell types upon MLL-ENL induction were correlated to normal HSCs and GMLPs (n = 4 and 3 microarray
samples per group) or normal pGMs and GMPs (n = 3 microarray samples in each group) for MLL-ENL-induced HSCs and pGMs, respectively. Shown are GSEA
enrichment plots of these analyses.
(C) Left: heatmap depicting the expression levels (log counts per million [CPM]) of genes belonging to the GO categories ‘‘Cell cycle arrest’’ and ‘‘Regulation of
cell cycle’’ inWT andMLL-ENL-induced pGMs andHSCs. Right: cell-cycle analysis of HSCs and pGMs cultured for 96 hr with andwithout Dox (n = 3,mean ±SD).
(D) Myeloid lineage contribution over time from 100 freshly isolated control HSCs or from 100 cultured HSCs (with or without Dox, n = 5 in each group,mean ±SD).
(E) Fetal liver HSC-derived myeloid contribution in mice that were given a standard dose of Dox pellets at week 16 posttransplantation (left: 200 HSCs/recipient,
n = 5 for the no-Dox group and n = 6 for the Dox group) and in the presence of a high concentration of Dox at 4 weeks posttransplantation (right: 100 HSCs/
recipient, n = 7 mice/group).
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mouse models, in contrast to retroviral delivery, is that in vitro
manipulations can be minimized. Our experimental approach is
therefore independent of the different sensitivities of different
cell types to in vitro manipulation.
Recent studies on both murine cells and primary human
samples proposed that gene-expression signatures imposed
upon the LICs at transformation share commonalities with
normal HSCs (Eppert et al., 2011; Krivtsov et al., 2006; Zhang
et al., 2013). Since normal HSCs already harbor an extensive
self-renewal capacity, a critical feature of leukemia, HSCs might
serve as a potent and susceptible target population for MLL-
ENL-induced leukemia. However, contrary to this expectation,
we found that HSCs were highly resistant to MLL-ENL-induced
transformation. At the same time, our in vitro experiments
demonstrated a gain of hyperproliferation to MLL-ENL following
only a few differentiation-associated HSC divisions. This is also a
highly relevant concern when interpreting results from retroviral
approaches, which require induction of proliferation for gene
delivery.
Studies on acute lymphoblastic leukemia, myelodysplastic
syndromes, chronic myelogenous leukemia, and de novo AML
have suggested a role for HSCs as a reservoir for accumulating
mutations in the preliminary phases of disease (Hong et al.,
2008; Jamieson et al., 2004; Jan et al., 2012; Klco et al.,
2014; Nilsson et al., 2002; Shlush et al., 2014). However,
because MLL leukemias have a short latency and fewer recur-
rent comutations than other genetic lesions that result in AML
(Cancer Genome Atlas Research Network, 2013), MLL-fusion
genes may not require such a cellular reservoir for further muta-
tions. This interpretation would perhaps be in line with the ob-
servations made here, since our gene-expression data suggest
that although MLL-ENL, regardless of the target cell, represents
a potent class II mutation (inhibition of differentiation), inherent
class I activity (extensive proliferation) is necessary for disease
propagation. However, our data on fetal liver HSCs, a state in
which HSCs proliferate more extensively, argue that the prolif-
erative status cannot be the sole factor that explains the
HSCs’ lack of LIC competence. Another outstanding question
that arises from our work is whether LICs are common for all
MLL fusions. For instance, mouse models of the MLL-AF4 or
reciprocal AF4-MLL fusions (rather than MLL-ENL or MLL-
AF9) produce alternative lymphoid or biphenotypic (rather
than exclusively myeloid) leukemias (Bursen et al., 2010; Chen
et al., 2006). We believe the relatively generic experimental
model/approach exploited here could be valuable for address-
ing this issue.
In conclusion, we have developed a mouse model that allows
for a conditional activation of the MLL-ENL oncogene in any
normal cell type of choice. Using this model, we observed
that overt transformation into AML is confined to a narrower
window of differentiation than was previously appreciated,
but the aggressiveness of disease can still be predicted from
the normal hierarchical position of the target cells. Moreover,
short-term in vitro differentiation could abrogate the hyperpro-
liferation mediated by MLL-ENL in otherwise leukemia-com-
petent cells. Together with the observation that HSCs do not
seem to be a prominent target of MLL-ENL-mediated transfor-
mation, these data argue that differentiation-based therapiesCell Reare a relevant avenue to pursue for clinical benefit in this
aggressive disease.
EXPERIMENTAL PROCEDURES
Generation of Col1a1-tetO-MLL/ENL Mice
The human MLL-ENL oncogene was subcloned into the EcoRI site of the
pBS31 vector and used to target KH2 ESCs (Beard et al., 2006). The engi-
neered ESCs were injected into E3.5 C57BL/6 blastocysts to generate
chimeric mice (Lund University Transgenic Animal Facility). MLL-ENL was
induced in vivo by administering Dox via standard food pellets (200 mg/kg;
Bio-Serv or ssniff Spezialdia¨ten) or, where indicated, high-Dox food pellets
(2g/kg; ssniff Spezialdia¨ten). Mice were maintained in the animal facilities at
the Biomedical Center of Lund University, and all animal experiments were
performed with the approval of the local ethics committee.
Cell Isolation and Adoptive Transfers
HSPCs were isolated as described previously (Figure S2A; Norddahl et al.,
2011; Pronk et al., 2007) from CD45.2+ Col1a1-tetO-MLL/ENL mice and
competitively transplanted into lethally irradiated (800 rad) young CD45.1
mice 3–4 hr after irradiation. For serial transplantation experiments, 5 3 106
unfractionated BM cells from primary diseased mice were transplanted
into sublethally irradiated (500 rad) CD45.1+ recipients (n = 3 recipients per
primary leukemia). Fetal liver HSCs were isolated from E14.5 embryos using
a LinSca1+c-kit+CD48CD150+ phenotype. Recipients were put on a
Dox-containing diet 5 days prior to transplantation. PB blood analyses were
conducted as described previously (Norddahl et al., 2011). Diseased mice
were subjected to Sysmex and necroscopic analyses. Survival rates were
plotted using the Kaplan-Meier method. Sudden elevations in donor myeloid
chimerism were considered events for plotting event-free survival. The
antibody clones and suppliers are provided in Supplemental Experimental
Procedures. Cells were sorted on a FACS Aria II or III cell sorter (Becton
Dickinson). All flow-cytometry and FACS data were analyzed using FlowJo
software (Treestar).
In Vitro Culture Assays
HSPCs were cultured in standard culture conditions (37C, 98% humidity, and
5% CO2) in OptiMEM (Invitrogen) supplemented with 10% fetal calf serum in
the presence of stem cell factor (10–50 ng/ml), interleukin-3 (5 ng/ml), and
granulocyte-colony stimulating factor (5 ng/ml) (all from PeproTech). Detailed
procedures for all in vitro experiments are described in the Supplemental
Experimental Procedures.
Quantitative RT-PCR
Quantitative RT-PCR was performed as described previously (Norddahl et al.,
2011). The procedure used for absolute quantification of mRNA and the
primers used for quantitative RT-PCR are listed in the Supplemental Experi-
mental Procedures.
Genome-Wide Expression Profiling
A total of 2,000 HSCs and pGMs (triplicates) from WT and Col1a1-tetO-MLL/
ENL mice were cultured in the presence of Dox for 48 hr. Cells were harvested
and total RNA was extracted using the RNeasy Micro Kit (Qiagen) for mRNA
purification. For details, see the Supplemental Experimental Procedures.
Statistical Analysis
Data were analyzed using Microsoft Excel (Microsoft, http://www.microsoft.
com) and GraphPad Prism (GraphPad Software). Significance values were
calculated by Student’s two-tailed t test or the log rank test (Mantel-Cox
test) for Kaplan-Meier curves.
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